APP substitutions V715F and L720P alter PS1 conformation and differentially affect Aβ and AICD generation
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The 37–43 amino acid Aβ peptide is the principal component of β‐amyloid deposits in Alzheimer's disease (AD) brain, and is derived by serial proteolysis of the amyloid precursor protein (APP) by β‐ and γ‐secretase. γ‐Secretase also cleaves APP at Val50 in the Aβ numbering (ε cleavage), resulting in the release of a fragment called APP intracellular domain (AICD). The aim of this study was to determine whether amino acid substitutions in the APP transmembrane domain differentially affect Aβ and AICD generation. We found that the APPV715F substitution, which has been previously shown to dramatically decrease Aβ 40 and Aβ 42 while increasing Aβ 38 levels, does not affect in vitro generation of AICD. Furthermore, we found that the APPL720P substitution, which has been previously shown to prevent in vitro generation of AICD, completely prevents Aβ generation. Using a fluorescence resonance energy transfer (FRET) method, we next found that both the APPV715F and APPL720P substitutions significantly increase the distance between the N‐ and C‐terminus of presenilin 1 (PS1), which has been proposed to contain the catalytic site of γ‐secretase. In conclusion, both APPV715F and APPL720P change PS1 conformation with differential effects on Aβ and AICD production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein
De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · cited 1×
“In addition to APP and Notch (De Strooper et al. 1998, 1999; Struhl and Greenwald 1999), several additional transmembrane proteins have been identified as c-secretase substrates (De Strooper 2003; Haass 2004; Kopan and Ilagan 2004), suggesting a role of presenilins/c-secretase in the cleavage of…”
BackgroundA subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity
Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · cited 1×
“Interestingly, some non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to selectively decrease the production of Ab42 and increase Ab38 levels, while not interfering with the generation of AICD, NICD and ErbB4 intracellular domain (Weggen et al. 2001, 2003).”
BackgroundSelf-citationAph-1, Pen-2, and Nicastrin with Presenilin Generate an Active γ-Secretase Complex
De Strooper, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00205-8 · Cited by 965 · cited 2×
“…Strooper et al. 1998, 1999; Struhl and Greenwald 1999), several additional transmembrane proteins have been identified as c-secretase substrates (De Strooper 2003; Haass 2004; Kopan and Ilagan 2004), suggesting a role of presenilins/c-secretase in the cleavage of transmembrane proteins involved in…”
BackgroundPhotoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1
Li, Y.-M., Xu, M., Lai, M.-T., Huang, Q., Castro, J. L., DiMuzio-Mower, J., Harrison, T., Lellis, C., Nadin, A., Neduvelil, J. G., et al. (2000) · Nature · doi:10.1038/35015085 · Cited by 866
Qi-Takahara, Y., Morishima-Kawashima, M., Tanimura, Y., Dolios, G., Hirotani, N., Horikoshi, Y., Kametani, F., Maeda, M., Saido, T. C., Wang, R., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1575-04.2005 · Cited by 391 · cited 6×
“2005), and that low concentrations of the dipeptide inhibitor, DAPT, inhibit Ab40 production while increasing levels of Ab1)46 (Zhao et al. 2004; Qi-Takahara et al. 2005).”
BackgroundSelf-citationMutations in APP have independent effects on Aβ and CTFγ generation
Hecimovic, S., Wang, J., Dolios, G., Martinez, M., Wang, R., & Goate, A. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.04.018 · Cited by 70 · cited 1×
“Accordingly, levels of AICD are independent of increased levels of Ab42 owing to either FAD or artificial mutations in APP (Bergman et al. 2003; Hecimovic et al. 2004).”
BackgroundSelf-citation
Cited by
Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
Kametani, F., & Hasegawa, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00025 · Cited by 836
“APP C-terminal fragments (Tesco et al., 2005; Wiley et al., 2005; Xu et al., 2016a), and such accumulation has been found even in sporadic AD brains (Pera et al.”
BackgroundProteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455
Substrate-targeting γ-secretase modulators
Kukar, T. L., Ladd, T. B., Bann, M. A., Fraering, P. C., Narlawar, R., Maharvi, G. M., Healy, B., Chapman, R., Welzel, A. T., Price, R. W., et al. (2008) · Nature · doi:10.1038/nature07055 · Cited by 280
Weggen, S., & Beher, D. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt107 · Cited by 192
Rogers, K., Felsenstein, K. M., Hrdlicka, L., Tu, Z., Albayya, F., Lee, W., Hopp, S., Miller, M.-J., Spaulding, D., Yang, Z., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-61 · Cited by 75
Metadata
- Authors
- Tesco, G., Ginestroni, A., Hiltunen, M., Kim, M., Dolios, G., Hyman, B. T., Wang, R., Berezovska, O., & Tanzi, R. E.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2005-09-12
- Volume
- 95
- Issue
- 2
- Pages
- 446-456
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1988762917
- Cited by
- 30
- References
- 6
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.